Skip to main content
OpenTrials
Completed

NCT Number: NCT04669951

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Esophagus Cancer, Adenocarcinoma Adenocarcinoma Adenocarcinoma Of Esophagus Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rigshospitalet

Copenhagen, Capital Region, 2100, Denmark

About this study

  • Sections of the tumor tissue will be HE stained.
  • Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry.
  • Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern.
  • A semiqualitative scale corresponding to the level of uPAR expression will be made.
  • Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern.
  • An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old.
  • Patients who underwent curatively intended surgery for gastroesophageal cancer
  • Patients who underwent surgery after 01-01-2016.

Exclusion criteria

  • Patients who applied for an exception from medical research at the "National Registry of Tissue Use."
  • Patients with other histological subtypes than adenocarcinoma.

Treatment and study plan

uPAR immunohistochemistry

Other

Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression

Primary outcomes

  1. uPAR microexpression

    Time frame: Up to 6 months

    Our primary objective is to investigate uPAR microexpression in gastroesophageal adenocarcinomas both qualitatively and semi-quantitatively. This will be done by a pathology analysis of gastroesophageal cancer resections.

  2. Tumor-to-background ratio

    Time frame: Up to 6 months

    A pathology staining will determine the uPAR in the tumor compared with the healthy cells.

Secondary outcomes

  1. uPAR in patient groups

    Time frame: Up to 6 months

    Baseline statistical analysis of patient groups and their expression of uPAR in their resected tumor tissues will be made.

Sponsors and collaborators

Lead sponsor

Michael Patrick Achiam

Other

Registry information

Official study title

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Dec 17, 2020
Registry last updated
Jun 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.